- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02788916
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas
A Retrospective Study of Clinical, Phenotypic and Genetic Factors of Peripheral T-Cell Lymphomas in the Spanish Population
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
This study is a retrospective, non-interventional and, post-authorization observational study of other designs (PAS-OD).
This multicenter trial will be conducted in Spain. Retrospective review of medical records and initial tumor biopsies of participants diagnosed with PTCL in the period of 6 years between 01/01/2008 and 31/12/2013 will be performed. Initial tumor biopsies and histological preparations, filed and previously anonymized, will be sent to the central laboratory for assessment.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Barcelona, Spanien
-
Cordoba, Spanien
-
Madrid, Spanien
-
Oviedo, Spanien
-
Salamanca, Spanien
-
Santander, Spanien
-
Sevilla, Spanien
-
Valencia, Spanien
-
-
A Coruna
-
Santiago de Compostela, A Coruna, Spanien
-
-
Madrid
-
Majadahonda, Madrid, Spanien
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Barn
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Participants diagnosed with PTCL in the six years between 01/01/2008 and 31/12/2013.
- Availability of initial tumor biopsy diagnosis in paraffin block (node or core biopsy of 16-18mm).
PTCL subtypes permitted by WHO 2008 classification of lymphoid neoplasms:
- Natural killer/ T-lymphocytes (NK /T-cell) lymphoma extranodal nasal type
- Enteropathic T-cell lymphoma
- Hepatosplenic T-cell lymphoma
- Peripheral T-cell lymphoma, not otherwise specified
- Angioimmunoblastic T-cell lymphoma
- Anaplastic large cell lymphoma, Anaplastic lymphoma kinase positive (ALK)+
- Anaplastic large cell lymphoma, ALK-
Exclusion Criteria:
• Participants with an unavailable history (lost, empty or not recoverable).
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
---|---|
Cohort 1
Assessment of tumor biopsies and histological preparations of participants diagnosed with peripheral T-cell lymphoma (PTCL) in the six years between 01 January 2008 and 31 December 2013 will be performed.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Distribution of Peripheral T-cell Lymphoma (PTCL) Subtypes
Tidsram: Up to 6 months
|
Distribution of PTCL subtypes by re-analysis and re-classification of samples according to the 2008 WHO classification of lymphoid neoplasms will be estimated.
|
Up to 6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Percentage of Participants with Each Subtypes of PTCL
Tidsram: Up to 6 months
|
Percentage of participants with each subtypes of PTCL according to the WHO 2008 classification of lymphoid neoplasms will be reported.
|
Up to 6 months
|
Rate of Discrepancy Between the Initial Diagnosis and Re-analysis and Re-classification
Tidsram: Up to 6 months
|
Rate of discrepancy between the initial diagnosis of PTCL in participants and diagnosis by re-analysis and re-classification according to the WHO 2008 classification will be determined.
|
Up to 6 months
|
Expression of Cluster of Differentiation 30 (CD30) by Immunohistochemistry and Quantitative Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) in Different Subtypes of PTCL
Tidsram: Up to 6 months
|
Expression of CD30 by immunohistochemistry and quantitative RT-PCR in different subtypes of PTCL will be determined.
|
Up to 6 months
|
Correlation Between the Expression of CD30 and Lymphoid Lineage
Tidsram: Up to 6 months
|
Markers of T and B cells will be used in order to determine if CD30 expression occurs in tumor cells or other B-lineage.
|
Up to 6 months
|
Correlation Between the Expression of CD30, Prognostic Indices Used In PTCL and Survival
Tidsram: Up to 6 months
|
Survival includes progression free survival: period from date of start of treatment until tumor progression or death, whichever occurs first.
Overall survival: period from date of diagnosis to the date of death.
|
Up to 6 months
|
Classification of Peripheral T-cell Lymphoma
Tidsram: Up to 6 months
|
The PTCL is classified according to the expression of CD30 and T-Cell Receptor ß (TCRß) and T-Cell Receptor γ (TCRγ) by immunohistochemistry (IHC).
|
Up to 6 months
|
T-cell Clonality in PTCL
Tidsram: Up to 6 months
|
Analysis of T-cell clonality in PTCL will be performed.
Clonality defines the profile of gene rearrangement of T cell receptor and allow establishing whether proliferation is monoclonal.
|
Up to 6 months
|
Correlation Between Most frequent Mutations and Clinical, Phenotypic Factors
Tidsram: Up to 6 months
|
Distribution of the most frequent mutations in tumors and its correlation with clinical and phenotypic factors will be determined.
|
Up to 6 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- Brentuximab-5012
- TAK-HEM-2015-01 (Registeridentifierare: AEMPS)
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Lymfom, T-cell, perifert
-
National Cancer Institute (NCI)AvslutadPerifert T-cellslymfom (PTCL) | T-cell prolymfocytisk leukemi | Kutant T-cellslymfom (CTCL) | T-cellslymfom återfallit | Vuxen T-cellsleukemi (ATL)Förenta staterna
-
Essen BiotechHar inte rekryterat ännuT-cellslymfom | T-cell prolymfocytisk leukemi | T-cell Akut lymfoblastisk leukemi | T-cellsleukemi | T-cellslymfom i CNS | T Cell Childhood ALLAKina
-
Novartis PharmaceuticalsAvslutadLeukemi-lymfom, vuxen T-cell | Kutant T-cellslymfomJapan
-
CelgeneAvslutadPerifert T-cellslymfom | Vuxen T-cell leukemi-lymfomJapan
-
National Cancer Institute (NCI)IndragenHepatospleniskt T-cellslymfom | Enteropati-associerat T-cellslymfom | Vuxen T-cell leukemi/lymfom | Extranodalt NK-/T-cellslymfom, nästyp | Monomorft epiteliotrofisk tarm T-cellslymfomFörenta staterna
-
John ReneauRekryteringÅterkommande primärt kutant T-cells non-Hodgkin-lymfom | Återkommande vuxen T-cell leukemi/lymfom | Refraktärt primärt kutant T-cells non-Hodgkin-lymfom | Refraktär vuxen T-cell leukemi/lymfomFörenta staterna
-
PersonGen BioTherapeutics (Suzhou) Co., Ltd.The First People's Hospital of Hefei; Hefei Binhu HospitalOkändAkut myeloid leukemi | Angioimmunoblastiskt T-cellslymfom | Hepatospleniskt T-cellslymfom | Prekursor T-cell lymfoblastisk leukemi-lymfom | Extranodalt NK/T-cellslymfom, nästyp | T-cell prolymfocytisk leukemi | T-cell stor granulär lymfatisk leukemi | Perifert T-cellslymfom, NOS | Intestinalt T-cellslymfom...Kina
-
Eisai Inc.AvslutadLymfom, T-cell, Perifert | Lymfom, T-cell, KutanJapan
-
Deepa JagadeeshRekryteringAngioimmunoblastiskt T-cellslymfom | T-cells lymfom | Vuxen T-cell leukemi/lymfom | Enteropati associerat T-cellslymfom | Lever-mjälte T-cellslymfom | NK T-cellslymfomFörenta staterna
-
University of NebraskaNational Cancer Institute (NCI); AmgenAvslutadPerifert T-cellslymfom | Anaplastiskt storcelligt lymfom | Angioimmunoblastiskt T-cellslymfom | Vuxen nästyp Extranodal NK/T-cellslymfom | Återkommande vuxen T-cell leukemi/lymfomFörenta staterna
Kliniska prövningar på Inget ingripande
-
Case Western Reserve UniversityAmerican University; Purdue UniversityRekrytering
-
Federal University of São PauloOkändHjärtkirurgi | Aorta No-touchBrasilien
-
Otsuka Pharmaceutical Factory, Inc.CelerionAvslutad
-
Seoul National University HospitalSamsung Medical Center; Chosun University HospitalAvslutadRadiofrekvensablation | MikrovågsablationKorea, Republiken av
-
University of MinnesotaAvslutad
-
Catharina Ziekenhuis EindhovenAvslutadVaskulära infektionerNederländerna
-
University of British ColumbiaAvslutadCentral Line komplikationKanada
-
Assistance Publique - Hôpitaux de ParisAvslutadSicklecellanemiFrankrike
-
Swiss Federal Institute of TechnologyInstituto de Investigação em ImunologiaAvslutadStörningar i järnmetabolism | Överbelastning av järn | PolyfenolerPortugal, Schweiz